Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial
- Resource Type
- Source
- The Lancet. Respiratory medicine, vol 7, iss 2
- Subject
Male ARDS Severity of Illness Index law.invention 0302 clinical medicine Randomized controlled trial law Stem Cell Research - Nonembryonic - Human Clinical endpoint Medicine 030212 general & internal medicine Hospital Mortality Prospective Studies Prospective cohort study Acute Respiratory Distress Syndrome Lung Academic Medical Centers Respiratory Distress Syndrome Statistics Middle Aged Editorial Commentary Treatment Outcome 6.1 Pharmaceuticals Respiratory Public Health and Health Services Female Patient Safety Pulmonary and Respiratory Medicine Adult medicine.medical_specialty Clinical Trials and Supportive Activities Clinical Sciences Placebo Mesenchymal Stem Cell Transplantation Risk Assessment Statistics, Nonparametric Disease-Free Survival 03 medical and health sciences Rare Diseases Double-Blind Method Clinical Research Internal medicine Severity of illness Humans Nonparametric Proportional Hazards Models Aged Intention-to-treat analysis Other Medical and Health Sciences business.industry Evaluation of treatments and therapeutic interventions medicine.disease Stem Cell Research Survival Analysis United States Clinical trial Good Health and Well Being 030228 respiratory system Multivariate Analysis business - Language